We are delighted to announce that Tim Wright, a highly experienced executive in policy, access, value and evidence has joined our team at Avalere Health as the new President of its global Policy, Access, Value, and Evidence capability. The announcement was made just before the Professional Society for Health Economics and Outcomes Research (ISPOR) Europe meeting in Copenhagen, Denmark, being held from November 12 to 15.

“Tim is an accomplished and respected leader who brings more than 30 years of global experience in pricing, reimbursement and market access consultancy,” said Amar Urhekar, Chief Operating Officer. “He has a wealth of knowledge and expertise in managing teams and succeeding in this complex environment. Tim will ensure we deliver our industry-leading solutions to clients as they engage with our community of experts.”

With Tim at the helm, our team will continue to increase its collaborative engagements with Avalere Health’s policy, market access, HEOR, and healthcare transformation colleagues in the U.S., closing the gap in executing market access strategies for global brand launches. When the agency rebranded in October, leading HEOR and market access consultancies, such as Policy Analysis Inc (PAI), Skysis and PRMA Consulting, retired their names to adopt the Avalere Health moniker to further emphasize the agency’s integrated service offerings. Together, the company’s experts deliver unrivaled global expertise from Europe to North America, Latin America and the Asia-Pacific region, with clients benefiting from connected solutions from pre-clinical to post-launch that span a range of services in Consulting; Medical; Policy, Access, Value, and Evidence; Marketing and Digital Experience Technology.

Tim’s experience draws from more than 1,000 global engagements and senior leadership roles at companies including Evidera, United BioSource Corporation and Total Healthcare Group. He also has 12 years of country, regional and global in-house expertise at leading biopharmaceutical companies, such as AstraZeneca, Janssen-Cilag U.K., Allergan and Astra.

“Everyone recognizes the policy and market access landscape is becoming more complex and challenging for our clients,” added Tim. “The ever-increasing pressure from payers, demand for real-world evidence data and scrutiny on pricing means our client partnerships need to be more meaningful, innovative and comprehensive. Our strategic expertise is bolstered by the ability to draw on our medical, marketing and consulting colleagues within the Avalere Health team. Together, we create the connection that make better health happen.”

Tim will be at ISPOR Europe meeting with clients and colleagues to emphasize how Avalere Health’s interdisciplinary team of strategists, scientists, analysts and technologists offer a 360-degree view of the landscape across the product lifecycle. These integrated services range from driving early asset investment strategies to assessing how legislative changes impact coverage and access and creating relevant experiences that evolve.

Booth C3-065 at ISPOR Europe: Optimizing decisions with on-demand HEOR analytics and expert insights

While at ISPOR Europe, Tim and the team from Avalere Health will demonstrate how its digital solution, hēR­o3 accelerates and empowers health economics and outcomes research (HEOR). hēR­o3 enables companies to leverage HEOR insights for early assets to make more data-driven decisions, optimizing clinical development programs and avoiding costly mistakes. The application combines recent advances in technology with the team’s in-house modeling expertise to rapidly deliver understandable HEOR insights in hours or days, ensuring HEOR teams can now contribute critical insights into decision-making when they are called upon.

“hēRo3 transforms how global companies make informed decisions from the start of the drug development process and we’re excited to share it with ISPOR Europe attendees,” noted Tim.

• Tim will be at the booth throughout Monday and Tuesday
• The hēRo3 demonstration will occur every day throughout the day.